Colin Groot

Colin Groot

Auto-generated profile, based on publicly available information

Colin Groot

Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands; and

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Ageing Research Reviews
Verified
Journal Article
Closed access
CGC. Groot
C. Groot
AHA.M. Hooghiemstra
A.M. Hooghiemstra
PRP.G.H.M. Raijmakers
P.G.H.M. Raijmakers
BBB.N.M. van Berckel
B.N.M. van Berckel
PSP. Scheltens
P. Scheltens
ROR. Ossenkoppele
R. Ossenkoppele

9 January 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
CGColin Groot
Colin Groot
ALAnna C. van Loenhoud
Anna C. van Loenhoud
FBFrederik Barkhof
Frederik Barkhof
BBBart N.M. van Berckel
Bart N.M. van Berckel
TKTeddy Koene
Teddy Koene
RORik Ossenkoppele
Rik Ossenkoppele
Objective To examine cross-sectional effects of cognitive reserve (CR) and brain reserve (BR) on cognition across the spectrum of Alzheimer disease (AD). Methods We included 663 AD biomarker–positive participants with dementia (probable AD, n = 462) or in the predementia stages (preclinical/prodromal AD, n = 201). Education was used as a proxy of CR and intracranial volume as a proxy of BR. Cognition was assessed across 5 domains (memory, attention, language, visuospatial, and executive functions). We performed multiple linear regression models to examine effects of CR and BR on cognitive domain Z scores, adjusted for cerebral atrophy. Furthermore, we assessed differences in effects according to disease stage and across degrees of total reserve using a 4-level variable (high CR/high BR, high CR/low BR, low CR/high BR, and low CR/low BR). Results We found positive, independent effects of both CR and BR across multiple cognitive domains. Stratification for disease stage showed that effects of CR on attention and executive functioning were greater in predementia than in dementia (β = 0.39 vs β = 0.21 [Welch t = 2.40, p < 0.01] and β = 0.46 vs β = 0.26 [t = 2.83, p < 0.01]). Furthermore, we found a linear trend for better cognitive performance in all domains in the high CR/high BR group, followed by high CR/low BR, low CR/high BR, and then low CR/low BR (p for trend <0.05). Conclusions CR and BR both independently mitigate cognitive symptoms in AD. The positive effect of CR is most strongly expressed in the predementia stages and the additive effects of high CR and BR are most beneficial.

14 May 2022 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
CGColin Groot
Colin Groot
CCClaudia Cicognola
Claudia Cicognola
DBDivya Bali
Divya Bali
GTGallen Triana-Baltzer
Gallen Triana-Baltzer
JDJeffrey L. Dage
Jeffrey L. Dage
OHOskar Hansson
Oskar Hansson
Background: Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer’s disease (AD) stages and for monitoring of treatment effects. Plasma measurements of phosphorylated tau (p-tau) are a promising biomarker for AD, but different assays show varying diagnostic and prognostic accuracies. The objective of this study was to determine the clinical performance of a novel plasma p-tau217 (p-tau217) assay, p-tau217+Janssen, and perform a head-to-head comparison to an established assay, plasma p-tau217Lilly, within two independent cohorts.Methods: The study consisted of two cohorts, cohort 1 (27 controls and 25 individuals with mild-cognitive impairment [MCI]) and cohort 2 including 147 individuals with MCI at baseline who were followed for an average of 4.92 (SD 2.09) years. Receiver operating characteristic analyses were used to assess the performance of both assays to detect amyloid-β status (+/−) in CSF, distinguish MCI from controls, and identify subjects who will convert from MCI to AD dementia. General linear and linear mixed-effects analyses were used to assess the associations between p-tau and baseline, and annual change in Mini-Mental State Examination (MMSE) scores. Spearman correlations were used to assess the associations between the two plasma measures, and Bland-Altmann plots were examined to assess the agreement between the assays.Results: Both assays showed similar performance in detecting amyloid-β status in CSF (plasma p-tau217+JanssenAUC = 0.91 vs plasma p-tau217LillyAUC = 0.89), distinguishing MCI from controls (plasma p-tau217+JanssenAUC = 0.91 vs plasma p-tau217LillyAUC = 0.91), and predicting future conversion from MCI to AD dementia (plasma p-tau217+JanssenAUC = 0.88 vs p-tau217LillyAUC = 0.89). Both assays were similarly related to baseline (plasma p-tau217+Janssenrho = −0.39 vs p-tau217Lillyrho = −0.35), and annual change in MMSE scores (plasma p-tau217+Janssenr= −0.45 vs p-tau217Lillyr= −0.41). Correlations between the two plasma measures were rho = 0.69,p< 0.001 in cohort 1 and rho = 0.70,p< 0.001 in cohort 2. Bland-Altmann plots revealed good agreement between plasma p-tau217+Janssenand plasma p-tau217Lillyin both cohorts (cohort 1, 51/52 [98%] within 95%CI; cohort 2, 139/147 [95%] within 95%CI).Conclusions: Taken together, our results indicate good diagnostic and prognostic performance of the plasma p-tau217+Janssenassay, similar to the p-tau217Lillyassay.

11 September 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
ALAnna Catharina van Loenhoud
Anna Catharina van Loenhoud
CGColin Groot
Colin Groot
JVJacob William Vogel
Jacob William Vogel
WFWiesje Maria van der Flier
Wiesje Maria van der Flier
RORik Ossenkoppele
Rik Ossenkoppele
Brain reserve is a concept introduced to explain why Alzheimer’s disease (AD) patients with a greater brain volume prior to onset of pathology generally have better clinical outcomes. In this review, we provide a historical background of the emergence of brain reserve and discuss several aspects that need further clarification, including the dynamic or static nature of the concept and its underlying mechanisms and clinical effect. We then describe how brain reserve has been operationalized over the years, and critically evaluate the use of intracranial volume (ICV) as the most widely used proxy for brain reserve. Furthermore, we perform a meta-analysis showing that ICV is associated with higher cognitive performance after adjusting for the presence and amount of pathology. Although we acknowledge its imperfections, we conclude that the use of ICV as a proxy for brain reserve is currently warranted. However, further development of more optimal measures of brain reserve as well as a more clearly defined theoretical framework is essential.

1 August 2024 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
CGColin Groot
Colin Groot
RSRuben Smith
Ruben Smith
LCLyduine E. Collij
Lyduine E. Collij
SMSophie E. Mastenbroek
Sophie E. Mastenbroek
ESErik Stomrud
Erik Stomrud
OHOskar Hansson
Oskar Hansson
Importance: An accurate prognosis is especially pertinent in mild cognitive impairment (MCI), when individuals experience considerable uncertainty about future progression.Objective: To evaluate the prognostic value of tau positron emission tomography (PET) to predict clinical progression from MCI to dementia.Design, Setting, and Participants: This was a multicenter cohort study with external validation and a mean (SD) follow-up of 2.0 (1.1) years. Data were collected from centers in South Korea, Sweden, the US, and Switzerland from June 2014 to January 2024. Participant data were retrospectively collected and inclusion criteria were a baseline clinical diagnosis of MCI; longitudinal clinical follow-up; a Mini-Mental State Examination (MMSE) score greater than 22; and available tau PET, amyloid-β (Aβ) PET, and magnetic resonance imaging (MRI) scan less than 1 year from diagnosis. A total of 448 eligible individuals with MCI were included (331 in the discovery cohort and 117 in the validation cohort). None of these participants were excluded over the course of the study.Exposures: Tau PET, Aβ PET, and MRI.Main Outcomes and Measures: Positive results on tau PET (temporal meta–region of interest), Aβ PET (global; expressed in the standardized metric Centiloids), and MRI (Alzheimer disease [AD] signature region) was assessed using quantitative thresholds and visual reads. Clinical progression from MCI to all-cause dementia (regardless of suspected etiology) or to AD dementia (AD as suspected etiology) served as the primary outcomes. The primary analyses were receiver operating characteristics.Results: In the discovery cohort, the mean (SD) age was 70.9 (8.5) years, 191 (58%) were male, the mean (SD) MMSE score was 27.1 (1.9), and 110 individuals with MCI (33%) converted to dementia (71 to AD dementia). Only the model with tau PET predicted all-cause dementia (area under the receiver operating characteristic curve [AUC], 0.75; 95% CI, 0.70-0.80) better than a base model including age, sex, education, and MMSE score (AUC, 0.71; 95% CI, 0.65-0.77; P = .02), while the models assessing the other neuroimaging markers did not improve prediction. In the validation cohort, tau PET replicated in predicting all-cause dementia. Compared to the base model (AUC, 0.75; 95% CI, 0.69-0.82), prediction of AD dementia in the discovery cohort was significantly improved by including tau PET (AUC, 0.84; 95% CI, 0.79-0.89; P < .001), tau PET visual read (AUC, 0.83; 95% CI, 0.78-0.88; P = .001), and Aβ PET Centiloids (AUC, 0.83; 95% CI, 0.78-0.88; P = .03). In the validation cohort, only the tau PET and the tau PET visual reads replicated in predicting AD dementia.Conclusions and Relevance: In this study, tau-PET showed the best performance as a stand-alone marker to predict progression to dementia among individuals with MCI. This suggests that, for prognostic purposes in MCI, a tau PET scan may be the best currently available neuroimaging marker.

27 March 2023 in Brain
Verified
Journal Article
Open access
PDF file
DBDiana I Bocancea
Diana I Bocancea
ASAnna L Svenningsson
Anna L Svenningsson
ALAnna C van Loenhoud
Anna C van Loenhoud
CGColin Groot
Colin Groot
FBFrederik Barkhof
Frederik Barkhof
RORik Ossenkoppele
Rik Ossenkoppele
Mechanisms of resilience against tau pathology in individuals across the Alzheimer’s disease spectrum are insufficiently understood. Longitudinal data are necessary to reveal which factors relate to preserved cognition (i.e. cognitive resilience) and brain structure (i.e. brain resilience) despite abundant tau pathology, and to clarify whether these associations are cross-sectional or longitudinal. We used a longitudinal study design to investigate the role of several demographic, biological and brain structural factors in yielding cognitive and brain resilience to tau pathology as measured with PET. In this multicentre study, we included 366 amyloid-β-positive individuals with mild cognitive impairment or Alzheimer’s disease dementia with baseline 18F-flortaucipir-PET and longitudinal cognitive assessments. A subset (n = 200) additionally underwent longitudinal structural MRI. We used linear mixed-effects models with global cognition and cortical thickness as dependent variables to investigate determinants of cognitive resilience and brain resilience, respectively. Models assessed whether age, sex, years of education, APOE-ε4 status, intracranial volume (and cortical thickness for cognitive resilience models) modified the association of tau pathology with cognitive decline or cortical thinning. We found that the association between higher baseline tau-PET levels (quantified in a temporal meta-region of interest) and rate of cognitive decline (measured with repeated Mini-Mental State Examination) was adversely modified by older age (Stβinteraction = −0.062, P = 0.032), higher education level (Stβinteraction = −0.072, P = 0.011) and higher intracranial volume (Stβinteraction = −0.07, P = 0.016). Younger age, higher education and greater cortical thickness were associated with better cognitive performance at baseline. Greater cortical thickness was furthermore associated with slower cognitive decline independent of tau burden. Higher education also modified the negative impact of tau-PET on cortical thinning, while older age was associated with higher baseline cortical thickness and slower rate of cortical thinning independent of tau. Our analyses revealed no (cross-sectional or longitudinal) associations for sex and APOE-ε4 status on cognition and cortical thickness. In this longitudinal study of clinically impaired individuals with underlying Alzheimer’s disease neuropathological changes, we identified education as the most robust determinant of both cognitive and brain resilience against tau pathology. The observed interaction with tau burden on cognitive decline suggests that education may be protective against cognitive decline and brain atrophy at lower levels of tau pathology, with a potential depletion of resilience resources with advancing pathology. Finally, we did not find major contributions of sex to brain nor cognitive resilience, suggesting that previous links between sex and resilience might be mainly driven by cross-sectional differences.